AAPL297.49+3.19 (+1.08%) ▲|ABBV234.67-0.10 (-0.04%) ▼|ABT91.05+0.52 (+0.57%) ▲|ACN129.20+2.19 (+1.72%) ▲|ADBE198.64+1.21 (+0.61%) ▲|AMAT588.23+2.35 (+0.40%) ▲|AMD518.61-1.24 (-0.24%) ▼|AMGN351.39+4.38 (+1.26%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN239.89+5.78 (+2.47%) ▲|AVGO384.07+3.92 (+1.03%) ▲|AXP342.76+4.98 (+1.47%) ▲|BA220.97+4.26 (+1.97%) ▲|BAC57.53-0.39 (-0.66%) ▼|BKNG182.11+13.17 (+7.80%) ▲|BLK982.52-32.81 (-3.23%) ▼|BMY55.09-0.44 (-0.79%) ▼|BNY145.28-2.01 (-1.36%) ▼|BRK-B497.07+4.26 (+0.86%) ▲|C143.40-1.57 (-1.08%) ▼|CAT1,000.35+16.11 (+1.64%) ▲|CL92.99+1.56 (+1.71%) ▲|CMCSA22.59-0.22 (-0.94%) ▼|COF201.81+4.00 (+2.02%) ▲|COP106.94-3.04 (-2.76%) ▼|COST961.11+3.43 (+0.36%) ▲|CRM154.33+0.91 (+0.59%) ▲|CSCO120.51-0.64 (-0.53%) ▼|CVS101.46-0.12 (-0.11%) ▼|CVX171.56-4.42 (-2.51%) ▼|DE609.73+17.79 (+3.01%) ▲|DHR187.97+9.00 (+5.03%) ▲|DIS102.29-1.24 (-1.20%) ▼|DUK125.18+0.13 (+0.10%) ▲|EMR142.20-0.94 (-0.66%) ▼|FDX313.03-4.21 (-1.33%) ▼|GD346.28-4.06 (-1.16%) ▼|GE367.55+11.08 (+3.11%) ▲|GEV1,063.92+28.94 (+2.80%) ▲|GILD125.47+0.42 (+0.34%) ▲|GM79.81+0.86 (+1.09%) ▲|GOOG347.89+1.81 (+0.52%) ▲|GOOGL348.75+2.66 (+0.77%) ▲|GS1,081.98-12.46 (-1.14%) ▼|HD340.26+15.81 (+4.87%) ▲|HON227.06+4.69 (+2.11%) ▲|IBM262.50-2.44 (-0.92%) ▼|INTC132.90+0.62 (+0.47%) ▲|INTU268.42+10.37 (+4.02%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ240.48+1.40 (+0.59%) ▲|JPM333.09-1.06 (-0.32%) ▼|KO81.24+0.93 (+1.15%) ▲|LIN521.77+9.51 (+1.86%) ▲|LLY1,109.80+2.72 (+0.25%) ▲|LMT493.50-10.17 (-2.02%) ▼|LOW220.88+7.34 (+3.44%) ▲|LRCX368.81-2.52 (-0.68%) ▼|MA493.69+5.62 (+1.15%) ▲|MCD274.21+2.55 (+0.94%) ▲|MDLZ62.15+1.09 (+1.79%) ▲|MDT80.65+0.02 (+0.02%) ▲|META560.77-1.43 (-0.25%) ▼|MMM167.73+5.89 (+3.64%) ▲|MO72.05+0.44 (+0.61%) ▲|MRK120.85+1.25 (+1.04%) ▲|MS221.35-4.69 (-2.07%) ▼|MSFT372.37-1.58 (-0.42%) ▼|MU1,037.63-14.15 (-1.34%) ▼|NEE86.79+0.36 (+0.41%) ▲|NFLX71.73-1.10 (-1.50%) ▼|NKE41.99-0.40 (-0.93%) ▼|NOW94.53-1.41 (-1.47%) ▼|NVDA199.69-0.32 (-0.16%) ▼|ORCL157.45-7.71 (-4.67%) ▼|PEP143.17+1.12 (+0.79%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG153.09+2.23 (+1.47%) ▲|PLTR113.22-3.48 (-2.98%) ▼|PM178.59-0.10 (-0.06%) ▼|QCOM196.22-7.92 (-3.88%) ▼|RTX185.84-0.55 (-0.30%) ▼|SBUX103.92+2.87 (+2.84%) ▲|SCHW91.38-1.79 (-1.92%) ▼|SO94.74-0.20 (-0.21%) ▼|SPG218.90+2.16 (+1.00%) ▲|T22.41-0.41 (-1.78%) ▼|TMO489.11+19.76 (+4.21%) ▲|TMUS182.76-1.81 (-0.98%) ▼|TSLA378.32-3.29 (-0.86%) ▼|TXN303.86-0.50 (-0.16%) ▼|UBER74.45+4.78 (+6.86%) ▲|UNH406.37-2.89 (-0.70%) ▼|UNP260.55+1.94 (+0.75%) ▲|UPS105.24-0.59 (-0.56%) ▼|USB60.02-0.03 (-0.05%) ▼|V331.70+3.22 (+0.98%) ▲|VZ45.58-1.16 (-2.47%) ▼|WFC83.89-0.24 (-0.29%) ▼|WMT119.52+0.10 (+0.08%) ▲|XOM136.44-3.29 (-2.35%) ▼|AAPL297.49+3.19 (+1.08%) ▲|ABBV234.67-0.10 (-0.04%) ▼|ABT91.05+0.52 (+0.57%) ▲|ACN129.20+2.19 (+1.72%) ▲|ADBE198.64+1.21 (+0.61%) ▲|AMAT588.23+2.35 (+0.40%) ▲|AMD518.61-1.24 (-0.24%) ▼|AMGN351.39+4.38 (+1.26%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN239.89+5.78 (+2.47%) ▲|AVGO384.07+3.92 (+1.03%) ▲|AXP342.76+4.98 (+1.47%) ▲|BA220.97+4.26 (+1.97%) ▲|BAC57.53-0.39 (-0.66%) ▼|BKNG182.11+13.17 (+7.80%) ▲|BLK982.52-32.81 (-3.23%) ▼|BMY55.09-0.44 (-0.79%) ▼|BNY145.28-2.01 (-1.36%) ▼|BRK-B497.07+4.26 (+0.86%) ▲|C143.40-1.57 (-1.08%) ▼|CAT1,000.35+16.11 (+1.64%) ▲|CL92.99+1.56 (+1.71%) ▲|CMCSA22.59-0.22 (-0.94%) ▼|COF201.81+4.00 (+2.02%) ▲|COP106.94-3.04 (-2.76%) ▼|COST961.11+3.43 (+0.36%) ▲|CRM154.33+0.91 (+0.59%) ▲|CSCO120.51-0.64 (-0.53%) ▼|CVS101.46-0.12 (-0.11%) ▼|CVX171.56-4.42 (-2.51%) ▼|DE609.73+17.79 (+3.01%) ▲|DHR187.97+9.00 (+5.03%) ▲|DIS102.29-1.24 (-1.20%) ▼|DUK125.18+0.13 (+0.10%) ▲|EMR142.20-0.94 (-0.66%) ▼|FDX313.03-4.21 (-1.33%) ▼|GD346.28-4.06 (-1.16%) ▼|GE367.55+11.08 (+3.11%) ▲|GEV1,063.92+28.94 (+2.80%) ▲|GILD125.47+0.42 (+0.34%) ▲|GM79.81+0.86 (+1.09%) ▲|GOOG347.89+1.81 (+0.52%) ▲|GOOGL348.75+2.66 (+0.77%) ▲|GS1,081.98-12.46 (-1.14%) ▼|HD340.26+15.81 (+4.87%) ▲|HON227.06+4.69 (+2.11%) ▲|IBM262.50-2.44 (-0.92%) ▼|INTC132.90+0.62 (+0.47%) ▲|INTU268.42+10.37 (+4.02%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ240.48+1.40 (+0.59%) ▲|JPM333.09-1.06 (-0.32%) ▼|KO81.24+0.93 (+1.15%) ▲|LIN521.77+9.51 (+1.86%) ▲|LLY1,109.80+2.72 (+0.25%) ▲|LMT493.50-10.17 (-2.02%) ▼|LOW220.88+7.34 (+3.44%) ▲|LRCX368.81-2.52 (-0.68%) ▼|MA493.69+5.62 (+1.15%) ▲|MCD274.21+2.55 (+0.94%) ▲|MDLZ62.15+1.09 (+1.79%) ▲|MDT80.65+0.02 (+0.02%) ▲|META560.77-1.43 (-0.25%) ▼|MMM167.73+5.89 (+3.64%) ▲|MO72.05+0.44 (+0.61%) ▲|MRK120.85+1.25 (+1.04%) ▲|MS221.35-4.69 (-2.07%) ▼|MSFT372.37-1.58 (-0.42%) ▼|MU1,037.63-14.15 (-1.34%) ▼|NEE86.79+0.36 (+0.41%) ▲|NFLX71.73-1.10 (-1.50%) ▼|NKE41.99-0.40 (-0.93%) ▼|NOW94.53-1.41 (-1.47%) ▼|NVDA199.69-0.32 (-0.16%) ▼|ORCL157.45-7.71 (-4.67%) ▼|PEP143.17+1.12 (+0.79%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG153.09+2.23 (+1.47%) ▲|PLTR113.22-3.48 (-2.98%) ▼|PM178.59-0.10 (-0.06%) ▼|QCOM196.22-7.92 (-3.88%) ▼|RTX185.84-0.55 (-0.30%) ▼|SBUX103.92+2.87 (+2.84%) ▲|SCHW91.38-1.79 (-1.92%) ▼|SO94.74-0.20 (-0.21%) ▼|SPG218.90+2.16 (+1.00%) ▲|T22.41-0.41 (-1.78%) ▼|TMO489.11+19.76 (+4.21%) ▲|TMUS182.76-1.81 (-0.98%) ▼|TSLA378.32-3.29 (-0.86%) ▼|TXN303.86-0.50 (-0.16%) ▼|UBER74.45+4.78 (+6.86%) ▲|UNH406.37-2.89 (-0.70%) ▼|UNP260.55+1.94 (+0.75%) ▲|UPS105.24-0.59 (-0.56%) ▼|USB60.02-0.03 (-0.05%) ▼|V331.70+3.22 (+0.98%) ▲|VZ45.58-1.16 (-2.47%) ▼|WFC83.89-0.24 (-0.29%) ▼|WMT119.52+0.10 (+0.08%) ▲|XOM136.44-3.29 (-2.35%) ▼|
24.7 C
New York
Wednesday, June 24, 2026

Tag: diseases

newssourceFORcompanyinformationcontent1marketreleases

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the "Series C Warrants") and Series D warrants to purchase up to 20,000,000 shares of common stock (the "Series D Warrants"), at a combined offering price of $0.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today...

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives “Oscar of Italian Dermatology”

Dr. Roberta Lotti honoured for a pioneering work on PC111, reinforcing Scinai's strategic option agreement to acquire the Italian biotech company Pincell srl. JERUSALEM, June 26,...

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio.

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity Novel Globin-Switching mechanism derived from...

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease

ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target

BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize

STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025...

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s HMBD-002 for further clinical development

BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal TherapySHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for...

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China’s NMPA

SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. 
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDiseases

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers